Fact.MR, a market research and competitive intelligence provider, has conducted a comprehensive analysis on the global ulcerative colitis therapeutics market, which is expected to rise at a CAGR of 5.1% over the forecast period (2021 to 2027).
The specific cause of ulcerative colitis is unknown; however genetic causes, environmental changes, or immune system failure are all possibilities. Simple healthy practices such as having short meals throughout the day, staying hydrated, avoiding greasy foods, and reducing high-fiber food intake can help prevent ulcerative colitis.
Therapy for ulcerative colitis has two basic objectives. The first is to reduce symptom severity and improve patient comfort, while also promoting gut repair. The second goal is to prevent further flare-ups. The goal of treatment is to reduce and control the disease’s indications and symptoms.
The global ulcerative colitis therapeutics market is primarily driven by an increase in the incidence of inflammatory bowel diseases, increase in ulcerative colitis cases, and development of ulcerative colitis-specific medications by a large number of key companies.
Key Takeaways from Market Study
- Global ulcerative colitis therapeutics market to reach US$ 19.9 Bn by 2027.
- Ulcerative proctitis segment is projected to reach around US$ 2.1 Bn by 2027.
- Market in Europe to record 4.2% CAGR over the forecast period of 2021-2027.
- Market in China forecast to reach US$ 1.4 Bn valuation by 2027.
“Increasing product releases & approvals, rise in active clinical studies, and growing research & development activities for the treatment of ulcerative colitis illness are likely to fuel market growth over the coming years,” says a Fact.MR analyst
Key market players are focusing on the development of novel treatments for severe conditions of ulcerative colitis. Companies are involved in the development of novel drugs for the treatment of ulcerative colitis.
To enter into new markets and obtain high market share, key firms are focusing their efforts on product expansions and the development of innovative therapies, particularly in emerging economies. Alliances are being formed regularly to diversify product portfolios and boost market share.
- In 2019, Abbvie Company finalized the acquisition of Allergan, allowing it to expand its pharmaceutical range and provide patients with more advanced therapies. Allergen created a monoclonal antibody known as brazikumab, which is used to treat ulcerative colitis and Crohn’s disease.
- In April 2021, Arena Pharmaceuticals, Inc. started a phase II clinical trial to see if oral etrasimod is an effective therapy for adults with moderately active ulcerative colitis.
More Valuable Insights on Offer
Fact.MR, in its new offering, presents an unbiased analysis of the global ulcerative colitis therapeutics market, presenting historical demand data (2017-2020) and forecast statistics for the period of 2021-2027.
The study divulges essential insights on the market on the basis of disease type (ulcerative proctitis, proctosigmoiditis, left-sided colitis, pancolitis or universal colitis, and fulminant colitis) and route of administration (oral and injectables), across five major regions (North America, Europe, Asia Pacific, Latin America, and MEA).
Fact.MR’s Domain Knowledge in Healthcare
Our healthcare consulting team guides organizations at each step of their business strategy by helping you understand how the latest influencers account for operational and strategic transformation in the healthcare sector. Our expertise in recognizing the challenges and trends impacting the global healthcare industry provides indispensable insights and support – encasing a strategic perspective that helps you identify critical issues and devise appropriate solutions.
For more information, refer to our market research report or contact the PR author.